You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Innovative Mitigation of Radiation Effects in Advanced Technology Nodes

    SBC: MICROELECTRONICS RESEARCH DEVELOPMENT CORPORATION            Topic: DTRA16A003

    Micro-RDC has developed portable radiation effects test structures that scale to new process nodes.These structures will enable the investigation of the effects of radiation on the new technology from the material processing level as well as the circuit level.Fabricating the chosen structures and the refinement of software to extract the model parameters will be completed in this effort.A suite of ...

    STTR Phase II 2018 Department of DefenseDefense Threat Reduction Agency
  2. Nucleobase aminosugars with reduced ototoxicity

    SBC: NUBAD LLC            Topic: Y

    PROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Targeting of the S1P Receptor, S1P1, and Nox4 as Therapeutic Approaches in ARDS

    SBC: RESTORE THERAPEUTICS LLC            Topic: NHLBI

    PROJECT SUMMARYAcute Respiratory Distress SyndromeARDSis a devastating syndrome that afflicts more thanpatients in United States alone and has an unacceptably high mortality rate ofCurrently there are no therapies that address the loss of lung vascular barrier integrityvascular leakage and alveolar flooding that are critical features of ARDS pathobiologyThe PI was the first to demonstrate that sph ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical studies of Selective and Orally Bioavailable Aurora B Inhibitors for the Treatment of AML

    SBC: SYNACTIX PHARMACEUTICALS, INC.            Topic: 102

    ABSTRACTThe Aurora Kinase FamilyAKFcomprises heavily pursued therapeutic targets for cancer because of their intimate involvement in cell division and tumor progressionNumerous therapeutic campaigns have been initiated against the AKFwith promising clinical successes emanating from strategies targeting either Aurora A or Aurora BHoweverthe US Food and Drug Administration has yet to approve a cance ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Continuous emulsion digital PCR (cdPCR) for low-cost, rapid, near point-of-care genotyping of non-small cell lung cancer

    SBC: DropWorks, Inc.            Topic: 102

    PROJECT SUMMARY Genotyping of cancer has become the standard of carewhere specific mutations in cancer driving genes have been shown to indicate sensitivity or resistance to targeted treatmentsSampling of cell free DNAcfDNAin blood plasma could provide a non invasive means of performing this genotypingbut current methods are too complexslowdaysand expensivehundreds of dollarsto make use of this in ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A ratcheting prosthetic partial finger using advanced rapid manufacturing technology

    SBC: POINT DESIGNS, LLC            Topic: NICHD

    The Point PartialA Ratcheting Prosthetic Partial FingerUsing Advanced Rapid Manufacturing Technology Project SummaryAbstract The goal of the proposed project is to develop a purely mechanicalratcheting prosthetic partial fingerthe Point Partialwhichhas an industry leading strength to weight ratiocan be operated unilaterallyone handedoffers anatomical rotation and flexion around the patient s proxi ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Peripheral FAAH inhibitor, URB937, as an opioid-sparing analgesic for chronic pain.

    SBC: ASPIREBIO CORP            Topic: 101

    PROJECT SUMMARY Opioid drugs are powerful analgesicsbut their side effect profile strongly limits their useIndeedtheir addictive properties have led to an epidemic of abuse in the US that accounts forof the global utilization of prescription opioid analgesics in the USwith a market of over $billion per yearPrevious studies have shown that the endocannabinoid neurotransmitteranandamidecontrols noci ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Quantitative Biotherapeutic Particle Characterization via Deep Neural Networks

    SBC: Ursa Analytics            Topic: 400

    Project SummaryDespite their many bene ts and common useprotein based drugs can elicit serious adverse side effectsMany of these side effects are believed to be caused by small protein aggregatesOne tool for measuring these particles in a high throughput fashion is Micro ow ImagingMFIMFI is commonly used in both academia and industry to characterize subvisible particlesthosem in sizein protein the ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government